USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
17 May 2022 | 02:45 PM GMT

DTx - Employers partnerships

Anchored by:

Jo Masterson
CEO and Co-Founder
2MORROW, INC

Participants:

Jo Masterson CEO and Co-Founder2Morrow, Inc
Jo Masterson
CEO and Co-Founder2Morrow, Inc
Anish Shindore Founder & Managing PartnerGSD Health
Anish Shindore
Founder & Managing PartnerGSD Health
Chris Cardinal CEOAmptify
Chris Cardinal
CEOAmptify
Haisung Lee Associate Vice PresidentSamsung Fire & Marine Insurance
Haisung Lee
Associate Vice PresidentSamsung Fire & Marine Insurance
Jin Lee Director of Digital HealthAstellas Pharma, Inc
Jin Lee
Director of Digital HealthAstellas Pharma, Inc
Joseph Rubinsztain CEOChronWell
Joseph Rubinsztain
CEOChronWell
Mithun Ratnakumar Director Technology Strategy & GovernanceGerresheimer
Mithun Ratnakumar
Director Technology Strategy & GovernanceGerresheimer
Sapan Anand Global Commercial Digital HealthJohnson & Johnson
Sapan Anand
Global Commercial Digital HealthJohnson & Johnson
SE
Stephen Egan DirectorRediCare
SE
Stephen Egan
DirectorRediCare

About this Meeting

What are the do’s and don’ts when approaching employers for DTx reimbursement? Join HealthXL in this meeting to share and learn from others’ experiences.  

We have seen a significant number of employers starting to incorporate DTx products into their benefits plans (such as Pear Therapeutics reSET, Freespira, etc). Why is this a good route to market for DTx companies? How do we build meaningful and sustainable partnerships with employers? In this session we will discuss:  

  • What products are a good fit for employer partnerships and why? E.g oncology might be less aligned with the employer-focused route to market compared to musculoskeletal pain management or other areas. 
  • What are employers’ requirements to partner (e.g integration capabilities, clinical and economic evidence, usability, data privacy & security, etc)? 
  • What are the pros and cons of targeting employers directly vs. going through resellers/broker platforms  
  • What are the implications of choosing the employer route to market? (e.g impact on the evidence generation process, pricing, marketing, organizational structure, etc) 
  • In a B2B2C model, how do we ensure patient activation and long-term engagement?